Table 4 Treatment-emergent adverse events
Palonosetron | Ondansetron | Total | |
|---|---|---|---|
(n = 48) | (n = 50) | (N = 98) | |
TEAEs | 43 (89.6) | 49 (98.0) | 92 (93.9) |
Treatment-related AEs | 5 (10.4) | 4 (8.0) | 9 (9.2) |
Serious TEAEs | 6 (12.5) | 8 (16.0) | 14 (14.3) |
Treatment-related serious TEAEs | 0 (0.0) | 1 (2.0) | 1 (1.0) |
Deaths | 0 (0.0) | 0 (0.0) | 0 (0.0) |